Opticon to merge with Immune Response Inc:
This article was originally published in Clinica
Opticon Medical, a privately owned development stage company, is to be acquired by Immune Response Inc of Englewood Colorado, in a deal which will give Opticon an OTC listing. Immune ends up with 20% of the equity of the merged company. Opticon, based in Dublin, Ohio, is developing the OPTICON, a proprietary, silicone, disposable, valved urinary tract catheter which does not require a system of collection tubes or bags. Immune has no connection with the Californian company, Immune Response Corporation.
You may also be interested in...
Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.